Pediatric Leukemia Adoptive Therapy (PLAT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced To Express a CD19-Specific Chimeric Antigen Receptor
Pediatric Leukemia Adoptive Therapy (PLAT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced To Express a CD19-Specific Chimeric Antigen Receptor is a PHASE1 clinical asset sponsored by Seattle Children's Hospital in B Cell Leukemia. SEO and diligence focus: Autologous CD19 CAR+ EGFTt + T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: B Cell Leukemia
Modality: protein therapy
Target: Autologous CD19 CAR+ EGFTt + T cells
Sponsor: Seattle Children's Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Autologous CD19 CAR+ EGFTt + T cells
View original source fields
Condition raw: B Cell Leukemia
Condition normalized: B Cell Leukemia
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Autologous CD19 CAR+ EGFTt + T cells
Target normalized: Autologous CD19 CAR+ EGFTt + T cells